LTG-001, a selective inhibitor for treatment of acute pain, was granted Fast Track designation by the Food and Drug Administration (FDA).

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Here's why four Motley Fool contributors think chip giants Nvidia ( NVDA -0.26%) and Micron Technologies ( MU -1.05%), travel services company Airbnb ( ABNB -0.83%), biotech behemoth Vertex ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...